The termination of the ATM program is a signal of financial discipline or reduced near-term capital needs, but investors should watch for final Q1 2026 financials and pipeline updates as the next catalyst. The strong cash position supports operations into 2028 as previously guided.
SYRE drugs
SYRE drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 14 $64.01entry
- T+1 · 7mo ago +7.78%α +7.01% · $68.99
- T+5 · 7mo ago +11.34%α +9.95% · $71.27
- T+20 · 6mo ago +19.40%α +13.11% · $76.43
- T+60 · 4mo ago +54.27%α +45.75% · $98.75
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Spyre Therapeutics reported preliminary cash of $741M as of March 31, 2026, including $30M from legacy asset sales, while terminating its ATM offering. The cash update is positive, but halting equity financing suggests caution despite strong liquidity.
Key Financial Metrics
Key Facts
- Company expects ~$741M in cash, cash equivalents, and marketable securities as of March 31, 2026
- Cash includes $30M from legacy asset disposition, $23M of which is expected to be paid to CVR holders in Q2 2026
- Terminated at-the-market (ATM) prospectus, halting common stock sales under the existing agreement
- Sales Agreement with TD Securities remains in effect; new prospectus would be needed to restart sales
- No financial results finalized; this filing provides only preliminary cash guidance
Financial Impact
$741M cash position as of March 31, 2026, up from $486.2M reported on September 30, 2025
Risk Factors
- Preliminary figures are subject to change upon audit and final closing procedures
- Termination of ATM may signal reduced confidence in near-term equity markets or strategic shift in capital raising
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-024906 |
| Document: 0001628280-26-024906-index-headers.html | 0001628280-26-024906 |
| Document: 0001628280-26-024906-index.html | 0001628280-26-024906 |
| Document: 0001628280-26-024906.txt | 0001628280-26-024906 |
| 8-K Data (Synthetic) | 0001628280-26-024906 |
Track record
36 reports on SYRE
8 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +54.27% at T+60 after the Apr 13, 2026 report. 15 of 21 went positive at some point.
Filters
- Nov 3, 202613d ago 8-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Bearish 5/10 Entry $99.04 Now $99.37 −0.33% settles Feb 2
- Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 9, 20265w ago SC 13D/A Neutral 3/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 7, 20265w ago 8-K Bearish 5/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 6, 20265w ago 424B5 Bearish 6/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 5, 20266w ago Press Release Bearish 6/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago 424B5 Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago Press Release Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 2, 20266w ago Insider Cluster Bearish 4/10 Entry $92.72 Now $99.37 −7.17% settles Dec 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers